Starpharma secures European (EMA) agreement on BV treatment Phase 3

Starpharma today announced that the Phase 3 clinical trial program for VivaGel® bacterial vaginosis (BV) treatment has now also been agreed with the European Medicines Agency (EMA).

Australian Financial Review: Starpharma’s ‘deep portfolio’ attracts investors

Australian Financial Review Journalist Claire Stewart investigates Starpharma’s continued resilience in a difficult market, noting the significance of its $32m capital raising at market price: As market volatility shakes investors’ confidence, the share prices of many research and development-focused companies are suffering as a result of increasing concerns about capital availability and funding issues.

But for Starpharma, a $260 million pharmaceutical company that develops polymer – or dendrimer – nanotechnology, equity has not been an issue.

This week it raised $32 million through a share placement to institutional investors and it will launch a retail share purchase plan to raise an additional $3 million, opening on November 23.

Australian Life Scientist: Starpharma raises $32m

Australian Life Scientist notes the significance of M&G’s investment in Starpharma: ‘Starpharma Holdings (ASX:SPL) has raised $32 million in a placement, and will seek a further $3 million in a SPP, to help fund clinical trials and new product development.’

AAP: Investors give Starpharma $32m boost

AAP analyses how M&G’s investment will advance Starpharma’s research portfolio:  ‘A $32 million cash injection has given a boost to biotech Starpharma's plans to carry out advanced tests of a treatment for a common bacterial infection in women.

 

Go to the article (external link)

Starpharma completes A$32 million placement; SPP to follow

 Starpharma is pleased to announce it has successfully raised A$32 million via a placement to international and domestic institutional, sophisticated and professional investors.  It is intended to offer eligible existing shareholders the opportunity to also participate via a Share Purchase Plan to raise up to a further A$3 million.

AGM Chairman's address & CEO presentation; Results of AGM

Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 10th November 2011. Results of voting were released following the meeting.

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Quarterly Cash Flow Report for the period ended 30 September 2011.

ABC Radio Australia – Innovations: VivaGel Phase 3 Trial Gets Go-Ahead from FDA

ABC Radio Innovations Host Desley Blanch interviews Starpharma CEO Dr Jackie Fairley about the significance of Starpharma receiving FDA approval for the commencement of a Phase III clinical trial testing VivaGel for the treatment of Bacterial Vaginosis.

 

Go to the article (external link)


Starpharma secures FDA agreement on BV treatment Phase 3

Starpharma today announced that the Phase 3 clinical trial program for the VivaGel® bacterial vaginosis (BV) treatment program has been agreed with the US FDA following recent positive trial results and subsequent End of Phase 2 Meeting.

Ms Zita Peach appointed Non-Executive Director

Starpharma today announced the appointment of Ms Zita Peach as a Non-Executive Director.

Zita has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.